These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 5452388)

  • 21. Metabolism of ethyl dibunate-14C: an antitussive drug.
    Megel H; Strauss R; Shemano I; Ho R; Beiler JM
    Biochem Pharmacol; 1966 Aug; 15(8):1177-83. PubMed ID: 5973161
    [No Abstract]   [Full Text] [Related]  

  • 22. [Creatine and creatinine--how to read its figures].
    Furukawa T; Sugita H
    Nihon Rinsho; 1971 Jan; 29():Suppl:245-9. PubMed ID: 4928269
    [No Abstract]   [Full Text] [Related]  

  • 23. The half-life of 131 I-insulin in different groups of patients compared with normal subjects.
    van Rooyen RJ; de Bruin EJ; Bieler EU; Hoog JM
    S Afr Med J; 1972 Dec; 46(49):1927-31. PubMed ID: 4631796
    [No Abstract]   [Full Text] [Related]  

  • 24. Imatinib for patients with liver or kidney dysfunction: no need to modify the dose.
    Judson IR
    J Clin Oncol; 2008 Feb; 26(4):521-2. PubMed ID: 18235112
    [No Abstract]   [Full Text] [Related]  

  • 25. Influence of range of renal function and liver disease on predictability of creatinine clearance.
    Hull JH; Hak LJ; Koch GG; Wargin WA; Chi SL; Mattocks AM
    Clin Pharmacol Ther; 1981 Apr; 29(4):516-21. PubMed ID: 7471619
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The impact of disease states as a modifying factor for nutrition toxicity.
    Russell RM
    Nutr Rev; 1997 Feb; 55(2):50-3. PubMed ID: 9155218
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Effect of damaged liver parenchyma, renal insufficiency and hemodialysis on the pharmacokinetics of cyclophosphamide and its activated metabolites].
    Wagner T; Heydrich D; Bartels H; Hohorst HJ
    Arzneimittelforschung; 1980; 30(9):1588-92. PubMed ID: 7193030
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phenylbutazone and isoniazid metabolism in patients with liver disease in relation to previous drug therapy.
    Levi AJ; Sherlock S; Walker D
    Lancet; 1968 Jun; 1(7555):1275-9. PubMed ID: 4172137
    [No Abstract]   [Full Text] [Related]  

  • 29. [Simulation of the biodynamics of glycodiazine with the analog computer].
    Riemann J; Röpke H; Gerhards E; Kolb KH; Gibian H
    Arzneimittelforschung; 1968 Nov; 18(11):1443-5. PubMed ID: 5756066
    [No Abstract]   [Full Text] [Related]  

  • 30. Clinical pharmacokinetics of sulphonylurea hypoglycaemic drugs.
    Balant L
    Clin Pharmacokinet; 1981; 6(3):215-41. PubMed ID: 7016385
    [No Abstract]   [Full Text] [Related]  

  • 31. Studies on metabolism of drugs. XII. Quantitative separation of metabolites in human and rabbit urine after oral administration of sulfamonomethoxine and sulfamethomidine.
    Ueda M; Tsurui Y; Koizumi T
    Chem Pharm Bull (Tokyo); 1972 Sep; 20(9):2042-6. PubMed ID: 4645222
    [No Abstract]   [Full Text] [Related]  

  • 32. The influence of host factors on drug response. VII. Renal diseases.
    Vesell ES
    Ration Drug Ther; 1981 Nov; 15(11):1-9. PubMed ID: 7345476
    [No Abstract]   [Full Text] [Related]  

  • 33. [Treatment of patients with disorders of the biotransformation function of the liver with (+)-cyanidanol-3].
    Jabłkowski M; Adamska-Dyniewska H; Dziekański S
    Pol Tyg Lek; 1987 Oct; 42(43):1355-8. PubMed ID: 3328178
    [No Abstract]   [Full Text] [Related]  

  • 34. Pharmacokinetic profile of trimethoprim in dog and man.
    Kaplan SA; Weinfeld RE; Cotler S; Abruzzo CW; Alexander K
    J Pharm Sci; 1970 Mar; 59(3):358-63. PubMed ID: 5416179
    [No Abstract]   [Full Text] [Related]  

  • 35. Metabolism and biliary excretion of arylaminosulphonic acids in the rat.
    McMahon KA; O'Reilly WJ
    Food Cosmet Toxicol; 1969 Sep; 7(5):497-500. PubMed ID: 5351714
    [No Abstract]   [Full Text] [Related]  

  • 36. Pharmacokinetics and pharmacodynamics of lobaplatin (D-19466) in patients with advanced solid tumors, including patients with impaired renal of liver function.
    Welink J; Boven E; Vermorken JB; Gall HE; van der Vijgh WJ
    Clin Cancer Res; 1999 Sep; 5(9):2349-58. PubMed ID: 10499604
    [TBL] [Abstract][Full Text] [Related]  

  • 37. D-glucose interactions with renal tubule cell surfaces.
    Silverman M; Aganon MA; Chinard FP
    Am J Physiol; 1970 Mar; 218(3):735-42. PubMed ID: 4905482
    [No Abstract]   [Full Text] [Related]  

  • 38. Evidence of the protective effect of l-arginine and vitamin D against monosodium glutamate-induced liver and kidney dysfunction in rats.
    Elbassuoni EA; Ragy MM; Ahmed SM
    Biomed Pharmacother; 2018 Dec; 108():799-808. PubMed ID: 30253372
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [The influence of physiopathologic and genetic factors on drug biotransformation].
    Orzechowska-Juzwenko K
    Pol Arch Med Wewn; 1997 Dec; 98(12):561-8. PubMed ID: 9640086
    [No Abstract]   [Full Text] [Related]  

  • 40. The renal handling of trimethoprim and sulphamethoxazole in man.
    Sharpstone P
    Postgrad Med J; 1969 Nov; 45():Suppl:38-42. PubMed ID: 5361308
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.